Phase 3 study for people with Non-Alcoholic Fatty Liver Disease

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 15 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor Akero Therapeutics, Inc
Registry number NCT06528314
Started 4 October 2024 Today 16 October 2026 Estimated completion 1 February 2030

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Akero Clinical Study Site Broadmeadow NSW Recruiting
Akero Clinical Study Site Coffs Harbour NSW Recruiting
Akero Clinical Study Site Kingswood NSW Recruiting
Akero Clinical Study Site Liverpool NSW Recruiting
Akero Clinical Study Site Westmead NSW Recruiting
Akero Clinical Study Site Herston QLD Recruiting
Akero Clinical Study Site Adelaide SA Recruiting
Akero Clinical Study Site Box Hill VIC Recruiting
Akero Clinical Study Site Clayton VIC Recruiting
Akero Clinical Study Site Epping VIC Recruiting
Akero Clinical Study Site Heidelberg VIC Recruiting
Akero Clinical Study Site Melbourne VIC Recruiting
Akero Clinical Study Site Murdoch WA Recruiting
Akero Clinical Study Site Nedlands WA Recruiting
Akero Clinical Study Site Perth WA Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 15 October 2026 · not medical advice

Who can join

Age 18 Years to 80 Years
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 2150

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Cohort 1: Biopsy proven compensated cirrhosis (fibrosis stage 4) due to NASH/MASH and NAS score of \>=3 (at least 1 in each category) or evidence of steatosis and 2 current features of metabolic comorbidities

* Cohort 2: Biopsy proven or non-invasively diagnosed compensated cirrhosis (fibrosis stage 4) due to NASH/MASH

Exclusion Criteria:

* Other causes of liver disease based on medical history and/or liver histology and/or central laboratory results

* Type 1 diabetes or unstable Type 2 diabetes

* Any current or prior history of decompensated liver disease

Other inclusion and exclusion criteria may apply.

Dates on the record

Started 4 October 2024
Estimated completion 1 February 2030
Registry last updated 13 October 2026
Checked by Voxsanity 15 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 13 October 2026.
  • This page last checked by Voxsanity: 15 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.